A Phase Ib/II Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Efficacy of SCTB35 in Patients with Systemic Lupus Erythematosus
Latest Information Update: 26 Feb 2025
At a glance
- Drugs SCTB 35 (Primary)
- Indications Systemic lupus erythematosus
- Focus Adverse reactions; Therapeutic Use
- Sponsors Sinocelltech
Most Recent Events
- 26 Feb 2025 New trial record